Immune Design is developing first-in-class immuno-oncology drug candidates designed to make a meaningful difference for cancer patients. Below, please find a list of our current clinical trials.
Follicular Non-Hodgkin’s Lymphoma: G100
Title: Phase 1/2 Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma
Objective: To evaluate the safety and tolerability of ascending doses of intratumoral G100 in patients with follicular non-Hodgkin’s lymphoma (NHL) receiving local radiation
More Information: clinicaltrials.gov identifier: NCT02501473